Table 1.
Baseline characteristics of enrolled patients.
| Clinical Characteristics | Total (n = 121) |
|---|---|
| Age (years) | 60.8 ± 10.6 |
| Sex | |
| Male | 104 (86.0%) |
| Female | 17 (14.0%) |
| Etiology | |
| HBV | 74 (61.2%) |
| HCV | 11 (9.1%) |
| Alcohol consumption | 32 (26.4%) |
| HBV + HCV | 2 (1.7%) |
| NASH | 2 (1.7%) |
| Tumor number | |
| Single | 67 (55.4%) |
| Multiple | 54 (44.6%) |
| Size of tumor (cm) | |
| ≤5 | 59 (48.8%) |
| >5 | 62 (51.2%) |
| Vessel invasion | |
| No | 79 (65.3%) |
| Yes | 42 (34.7%) |
| TNM stage | |
| I | 51 (42.1%) |
| II | 15 (12.4%) |
| III | 13 (10.7%) |
| IV | 42 (34.7%) |
| BCLC stage | |
| 0/A | 59 (48.8%) |
| B/C | 62 (51.2%) |
| CTP class | |
| A | 104 (86.0%) |
| B | 17 (14.0%) |
| AST (U/L) | 50.0 [29.0–74.0] * |
| ALT (U/L) | 37.0 [25.0–53.0] * |
| Total bilirubin (mg/dL) | 0.7 [0.5–1.1] * |
| Albumin (g/dL) | 3.9 [3.5–4.2] * |
| Prothrombin time (s) | 12.5 [11.8–13.2] * |
| AFP (ng/mL) | 57.9 [7.5;2376.0] * |
HBV—hepatitis B virus; HCV—hepatitis C virus; NASH—nonalcoholic steatohepatitis; TNM—tumor-node metastasis; BCLC—Barcelona Clinic Liver Cancer; CTP—Child–Turcotte–Pugh; AST—aspartate transaminase; ALT—alanine transaminase; AFP—α-fetoprotein; * median [25–75% interquartile range].